Detalhe da pesquisa
1.
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
J Card Fail
; 29(6): 968-973, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37031887
2.
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
N Engl J Med
; 381(17): 1609-1620, 2019 10 24.
Artigo
Inglês
| MEDLINE | ID: mdl-31475794
3.
Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
Circulation
; 142(13): 1236-1245, 2020 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-32845715
4.
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Circulation
; 141(5): 352-361, 2020 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31736342
5.
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation
; 141(5): 338-351, 2020 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31736337
6.
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
Eur Heart J
; 41(25): 2356-2362, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32221596
7.
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
JAMA
; 326(19): 1919-1929, 2021 11 16.
Artigo
Inglês
| MEDLINE | ID: mdl-34783839
8.
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
Circulation
; 140(17): 1369-1379, 2019 10 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31510768
9.
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Eur Heart J
; 38(15): 1132-1143, 2017 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-28158398
10.
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Circulation
; 133(23): 2254-62, 2016 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27143684
11.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med
; 371(11): 993-1004, 2014 Sep 11.
Artigo
Inglês
| MEDLINE | ID: mdl-25176015
12.
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Am Heart J
; 188: 35-41, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-28577679
13.
Sacubitril/Valsartan (LCZ696) in Heart Failure.
Handb Exp Pharmacol
; 243: 133-165, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28004291
14.
Geographic variations in the PARADIGM-HF heart failure trial.
Eur Heart J
; 37(41): 3167-3174, 2016 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27354044
15.
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Circulation
; 131(1): 54-61, 2015 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25403646
16.
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Eur Heart J
; 36(38): 2576-84, 2015 Oct 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26231885
17.
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Eur Heart J
; 36(30): 1990-7, 2015 Aug 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26022006
18.
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Eur Heart J
; 36(7): 434-9, 2015 Feb 14.
Artigo
Inglês
| MEDLINE | ID: mdl-25416329
19.
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Lancet
; 380(9851): 1387-95, 2012 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-22932717
20.
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
N Engl J Med
; 373(23): 2289-90, 2015 Dec 03.
Artigo
Inglês
| MEDLINE | ID: mdl-26630151